{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:30:23Z","timestamp":1767151823799,"version":"build-2238731810"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Coronavirus disease 2019 (COVID-19) in kidney transplant recipients is a subject of much debate and became of interest to nephrologists amidst the pandemic. The main concerns are the influence of the chronic use of immunosuppressive drugs, the viral-related risk of acute rejection, and the long-term outcome of allograft function. This single-center prospective study included kidney transplant recipients with COVID-19 infection. Patients were maintained on immunosuppressive regimens. The severity of disease was defined as oxygen saturation\u2009&lt;\u200994%, the need for hospitalization and\/or hemodialysis, the occurrence of acute kidney injury (AKI), and mortality. Seventeen patients (54.8%) required hospital admission, four patients needed hemodialysis (12.9%), twelve patients (38.7%) had AKI, and three patients died (9.7%). Oxygen saturation\u2009&lt;\u200994% showed a positive correlation with the presence of diabetes (p value 0.031) and a negative correlation with the maintenance steroid dose (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.046). A negative correlation existed between the need for hemodialysis and average Cyclosporin level (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.019) and between the need for hospitalization and average Tacrolimus level (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.046). Severity of disease was associated with the presence of lymphopenia (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.042), the cumulative steroid dose (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.001), increased serum levels of LDH (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.010), Ferritin (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.020), AST (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.047), and ALT (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.006) and D-dimer levels more than 0.5\u00a0mg\/L (\n                    <jats:italic>p<\/jats:italic>\n                    value 0.038). This study highlighted that the immunocompromised state of renal transplant recipients may not be regarded as a disadvantage in the setting of COVID-19 infection. Studies on a larger scale are needed to validate these results.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-45750-8","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:02:27Z","timestamp":1698994947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of COVID-19 in Egyptian living-donor kidney transplant recipients and relation to maintenance immunosuppressive drugs: a pilot study"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2488-4440","authenticated-orcid":false,"given":"Maggie Said","family":"ElNahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-9270","authenticated-orcid":false,"given":"Marianne Samir Makboul","family":"Issac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-637X","authenticated-orcid":false,"given":"Khaled Marzouk","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"2020","key":"45750_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tmrv.2020.02.003","volume":"34","author":"L Chang","year":"2019","unstructured":"Chang, L., Yan, Y., Wang, L. & Disease, C. Coronaviruses and blood safety. Transfus. Med. Rev. 34(2020), 75\u201380. https:\/\/doi.org\/10.1016\/j.tmrv.2020.02.003 (2019).","journal-title":"Transfus. Med. Rev."},{"key":"45750_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.ekir.2020.08.017","volume":"5","author":"KL Lentine","year":"2020","unstructured":"Lentine, K. L. et al. Survey of US living kidney donation and transplantation practices in the COVID-19 Era. Kidney Int. Rep. 5, 1894\u20131905. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.017 (2020).","journal-title":"Kidney Int. Rep."},{"key":"45750_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12882-022-02784-w","volume":"23","author":"E Demir","year":"2022","unstructured":"Demir, E. et al. COVID-19 in kidney transplant recipients: A multicenter experience from the first two waves of pandemic. BMC Nephrol. 23, 183. https:\/\/doi.org\/10.1186\/s12882-022-02784-w (2022).","journal-title":"BMC Nephrol."},{"key":"45750_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3389\/fphar.2020.01333","volume":"11","author":"TS Schoot","year":"2020","unstructured":"Schoot, T. S., Kerckhoffs, A. P. M., Hilbrands, L. B. & van Marum, R. J. Immunosuppressive drugs and COVID-19: A review. Front. Pharmacol. 11, 1333. https:\/\/doi.org\/10.3389\/fphar.2020.01333 (2020).","journal-title":"Front. Pharmacol."},{"key":"45750_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.39339.610000.BE","volume":"335","author":"MDE Goodyear","year":"2007","unstructured":"Goodyear, M. D. E., Krleza-Jeric, K. & Lemmens, T. The declaration of Helsinki. BMJ. 335, 624\u2013625. https:\/\/doi.org\/10.1136\/bmj.39339.610000.BE (2007).","journal-title":"BMJ."},{"key":"45750_CR6","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 120, c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789 (2012).","journal-title":"Nephron Clin. Pract."},{"key":"45750_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/s0041-1345(01)02844-5","volume":"34","author":"T B\u0105czkowska","year":"2002","unstructured":"B\u0105czkowska, T. et al. Cyclosporine blood concentration at 2 hours (C2) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients\u2014A four-year follow-up. Transpl. Proc. 34, 556\u2013557. https:\/\/doi.org\/10.1016\/s0041-1345(01)02844-5 (2002).","journal-title":"Transpl. Proc."},{"key":"45750_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41563-020-00906-z","volume":"20","author":"BD Kevadiya","year":"2021","unstructured":"Kevadiya, B. D. et al. Diagnostics for SARS-CoV-2 infections. Nat. Mater. 20, 593\u2013605. https:\/\/doi.org\/10.1038\/s41563-020-00906-z (2021).","journal-title":"Nat. Mater."},{"key":"45750_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab048","author":"KE Hanson","year":"2021","unstructured":"Hanson, K. E. et al. The infectious diseases society of america guidelines on the diagnosis of COVID-19: Molecular diagnostic testing. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab048 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"45750_CR10","unstructured":"Ministry of Health and Population, Egyptian National Guidelines for COVID-19, (2020)."},{"key":"45750_CR11","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 56, 105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949 (2020).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"45750_CR12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.mayocp.2020.04.027","volume":"95","author":"P Vijayvargiya","year":"2020","unstructured":"Vijayvargiya, P. et al. Treatment considerations for COVID-19: A critical review of the evidence (or Lack thereof). Mayo Clin. Proc. 95, 1454\u20131466. https:\/\/doi.org\/10.1016\/j.mayocp.2020.04.027 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"45750_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000187007","volume":"62","author":"N Nampoory","year":"1992","unstructured":"Nampoory, N., Nessim, J., Gupta, R. K. & Johny, K. V. Drug interaction of chloroquine with ciclosporin. Nephron 62, 108\u2013109. https:\/\/doi.org\/10.1159\/000187007 (1992).","journal-title":"Nephron"},{"key":"45750_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000187506","volume":"65","author":"P Finielz","year":"1993","unstructured":"Finielz, P., Gendoo, Z., Chuet, C. & Guiserix, J. Interaction between cyclosporin and chloroquine. Nephron 65, 333. https:\/\/doi.org\/10.1159\/000187506 (1993).","journal-title":"Nephron"},{"key":"45750_CR15","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1111\/ajt.15943","volume":"20","author":"S Meziyerh","year":"2020","unstructured":"Meziyerh, S. et al. Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. Am. J. Transpl. 20, 1896\u20131901. https:\/\/doi.org\/10.1111\/ajt.15943 (2020).","journal-title":"Am. J. Transpl."},{"key":"45750_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1473-3099(07)70187-1","volume":"7","author":"NJ White","year":"2007","unstructured":"White, N. J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7, 549\u2013558. https:\/\/doi.org\/10.1016\/s1473-3099(07)70187-1 (2007).","journal-title":"Lancet Infect. Dis."},{"key":"45750_CR17","doi-asserted-by":"publisher","unstructured":"R.C. Group, P. Horby, et al. (2021) Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 DOI: https:\/\/doi.org\/10.1056\/NEJMoa2021436.","DOI":"10.1056\/NEJMoa2021436"},{"key":"45750_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/cid\/ciaa478","volume":"78","author":"A Bhimraj","year":"2020","unstructured":"Bhimraj, A. et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis. 78, 478. https:\/\/doi.org\/10.1093\/cid\/ciaa478 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"45750_CR19","doi-asserted-by":"publisher","first-page":"i21","DOI":"10.1093\/ckj\/sfab030","volume":"14","author":"N Toapanta","year":"2021","unstructured":"Toapanta, N. et al. Kidney transplantation and COVID-19 renal and patient prognosis. Clin. Kidney J. 14, i21\u2013i29. https:\/\/doi.org\/10.1093\/ckj\/sfab030 (2021).","journal-title":"Clin. Kidney J."},{"key":"45750_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.2117","volume":"109","author":"GW Strohbehn","year":"2021","unstructured":"Strohbehn, G. W. et al. COVIDOSE: A phase II clinical trial of low-dose tocilizumab in the treatment of noncritical COVID-19 pneumonia. Clin. Pharmacol. Ther. 109, 688\u2013696. https:\/\/doi.org\/10.1002\/cpt.2117 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"45750_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40266-020-00812-8","volume":"37","author":"D Cattaneo","year":"2020","unstructured":"Cattaneo, D. et al. Drug-drug interactions and prescription appropriateness in patients with COVID-19: A retrospective analysis from a reference hospital in Northern Italy. Drugs Aging. 37, 925\u2013933. https:\/\/doi.org\/10.1007\/s40266-020-00812-8 (2020).","journal-title":"Drugs Aging."},{"key":"45750_CR22","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.ekir.2021.06.023","volume":"6","author":"A Buxeda","year":"2021","unstructured":"Buxeda, A. et al. Use and safety of remdesivir in kidney transplant recipients with COVID-19. Kidney Int. Rep. 6, 2305\u20132315. https:\/\/doi.org\/10.1016\/j.ekir.2021.06.023 (2021).","journal-title":"Kidney Int. Rep."},{"key":"45750_CR23","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","volume":"4","author":"KM Andersen","year":"2022","unstructured":"Andersen, K. M. et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the national COVID cohort collaborative. Lancet heumatol. 4, e33\u2013e41. https:\/\/doi.org\/10.1016\/S2665-9913(21)00325-8 (2022).","journal-title":"Lancet heumatol."},{"key":"45750_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ijlh.13336","volume":"43","author":"J Nugroho","year":"2020","unstructured":"Nugroho, J. et al. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients: A meta-analysis. Int. J. Lab. Hematol. 43, 110\u2013115. https:\/\/doi.org\/10.1111\/ijlh.13336 (2020).","journal-title":"Int. J. Lab. Hematol."},{"key":"45750_CR25","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1111\/ajt.16246","volume":"20","author":"A Fav\u00e0","year":"2020","unstructured":"Fav\u00e0, A. et al. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. Am. J. Transpl. 20, 3030\u20133041. https:\/\/doi.org\/10.1111\/ajt.16246 (2020).","journal-title":"Am. J. Transpl."},{"key":"45750_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/phar.2410","volume":"40","author":"KM Johnson","year":"2020","unstructured":"Johnson, K. M., Belfer, J. J., Peterson, G. R., Boelkins, M. R. & Dumkow, L. E. Managing COVID-19 in renal transplant recipients: A review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy 40, 517\u2013524. https:\/\/doi.org\/10.1002\/phar.2410 (2020).","journal-title":"Pharmacotherapy"},{"key":"45750_CR27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.kint.2020.03.018","volume":"97","author":"D Banerjee","year":"2020","unstructured":"Banerjee, D. et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 97, 1076\u20131082. https:\/\/doi.org\/10.1016\/j.kint.2020.03.018 (2020).","journal-title":"Kidney Int."},{"key":"45750_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/IJNRD.S13866","volume":"3","author":"V Vivek","year":"2010","unstructured":"Vivek, V. & Bhandari, S. Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients. Int. J. Nephrol. Renovasc. Dis. 3, 175\u2013182. https:\/\/doi.org\/10.2147\/IJNRD.S13866 (2010).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"45750_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/ajt.15869","volume":"20","author":"L Zhu","year":"2020","unstructured":"Zhu, L. et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am. J. Transpl. 20, 1859\u20131863. https:\/\/doi.org\/10.1111\/ajt.15869 (2020).","journal-title":"Am. J. Transpl."},{"key":"45750_CR30","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/jcm9061753","volume":"9","author":"J Baj","year":"2020","unstructured":"Baj, J. et al. COVID-19 specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J. Clin. Med. 9, 1753. https:\/\/doi.org\/10.3390\/jcm9061753 (2020).","journal-title":"J. Clin. Med."},{"key":"45750_CR31","doi-asserted-by":"publisher","first-page":"1901826","DOI":"10.1183\/13993003.01826-2019","volume":"56","author":"L Sauerhering","year":"2020","unstructured":"Sauerhering, L. et al. Cyclophilin inhibitors restrict the Middle East respiratory syndrome coronavirus via interferon-\u03bb in vitro and mice. Eur. Respir. J. 56, 1901826. https:\/\/doi.org\/10.1183\/13993003.01826-2019 (2020).","journal-title":"Eur. Respir. J."},{"key":"45750_CR32","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/ajt.15905","volume":"20","author":"A Romanelli","year":"2020","unstructured":"Romanelli, A. & Mascolo, S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis. Am. J. Transplant. 20, 1947\u20131948. https:\/\/doi.org\/10.1111\/ajt.15905 (2020).","journal-title":"Am. J. Transplant."},{"key":"45750_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2020.03.022","volume":"94","author":"T Xu","year":"2020","unstructured":"Xu, T. et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. Int. J. Infect. Dis. 94, 68\u201371. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.022 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"45750_CR34","first-page":"711","volume":"58","author":"C Eastin","year":"2020","unstructured":"Eastin, C. & Eastin, T. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 58, 711\u2013712 (2020).","journal-title":"N. Engl. J. Med."},{"key":"45750_CR35","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1093\/ckj\/sfab107","volume":"14","author":"JH Ng","year":"2021","unstructured":"Ng, J. H., Zaidan, M., Jhaveri, K. D. & Izzedine, H. Acute tubulointerstitial nephritis and COVID-19. Clin. Kidney J. 14, 2151\u20132157. https:\/\/doi.org\/10.1093\/ckj\/sfab107 (2021).","journal-title":"Clin. Kidney J."},{"key":"45750_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/biom12020298","volume":"12","author":"A Gambella","year":"2022","unstructured":"Gambella, A. et al. Spectrum of kidney injury following COVID-19 disease: Renal biopsy findings in a single italian pathology service. Biomolecules 12, 298. https:\/\/doi.org\/10.3390\/biom12020298 (2022).","journal-title":"Biomolecules"},{"key":"45750_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1590\/2175-8239-JBN-2020-0144","volume":"43","author":"RL da Costa","year":"2021","unstructured":"da Costa, R. L. et al. Acute kidney injury in patients with Covid-19 in a Brazilian ICU: Incidence, predictors and in-hospital mortality. J. Bras. Nefrol. 43, 349\u2013358. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2020-0144 (2021).","journal-title":"J. Bras. Nefrol."},{"key":"45750_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.kint.2020.05.006","volume":"98","author":"JS Hirsch","year":"2020","unstructured":"Hirsch, J. S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 98, 209\u2013218. https:\/\/doi.org\/10.1016\/j.kint.2020.05.006 (2020).","journal-title":"Kidney Int."},{"key":"45750_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12882-021-02617-2","volume":"22","author":"PD Jewell","year":"2021","unstructured":"Jewell, P. D. et al. Correction to: COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. BMC Nephrol. 22, 403. https:\/\/doi.org\/10.1186\/s12882-021-02617-2 (2021).","journal-title":"BMC Nephrol."},{"key":"45750_CR40","doi-asserted-by":"publisher","first-page":"719472","DOI":"10.3389\/fmed.2021.719472","volume":"8","author":"X Cai","year":"2021","unstructured":"Cai, X., Wu, G., Zhang, J. & Yang, L. Risk factors for acute kidney injury in adult patients with COVID-19: A systematic review and meta-analysis. Front. Med. 8, 719472. https:\/\/doi.org\/10.3389\/fmed.2021.719472 (2021).","journal-title":"Front. Med."},{"key":"45750_CR41","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41581-020-00356-5","volume":"16","author":"MK Nadim","year":"2020","unstructured":"Nadim, M. K. et al. COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality initiative (ADQI) Workgroup. Nat. Rev. Nephrol. 16, 747\u2013764. https:\/\/doi.org\/10.1038\/s41581-020-00356-5 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"45750_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ekir.2020.10.023","volume":"6","author":"V Mahalingasivam","year":"2021","unstructured":"Mahalingasivam, V. et al. A systematic review of COVID-19 and kidney transplantation. Kidney Int. Rep. 6, 24\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2020.10.023 (2021).","journal-title":"Kidney Int. Rep."},{"key":"45750_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","volume":"146","author":"T Herold","year":"2020","unstructured":"Herold, T. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 146, 128-136.e4. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.008 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"45750_CR44","doi-asserted-by":"publisher","first-page":"e1292","DOI":"10.1097\/TXD.0000000000001292","volume":"8","author":"A Devresse","year":"2022","unstructured":"Devresse, A. et al. Immunosuppression and SARS-CoV-2 infection in kidney transplant recipients, transplant. Direct 8, e1292\u2013e1292. https:\/\/doi.org\/10.1097\/TXD.0000000000001292 (2022).","journal-title":"Direct"},{"key":"45750_CR45","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/ehf2.13548","volume":"8","author":"J Yoo","year":"2021","unstructured":"Yoo, J. et al. Admission NT-proBNP and outcomes in patients without a history of heart failure hospitalized with COVID-19. ESC Hear. Fail. 8, 4278\u20134287. https:\/\/doi.org\/10.1002\/ehf2.13548 (2021).","journal-title":"ESC Hear. Fail."},{"issue":"7","key":"45750_CR46","doi-asserted-by":"publisher","first-page":"614","DOI":"10.34067\/KID.0002652020","volume":"1","author":"MM Mohamed","year":"2020","unstructured":"Mohamed, M. M. et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney 1(7), 614 (2020).","journal-title":"Kidney"},{"issue":"3","key":"45750_CR47","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/ajt.16424","volume":"21","author":"S Caillard","year":"2021","unstructured":"Caillard, S. et al. Is COVID-19 infection more severe in kidney transplant recipients?. Am. J. Transpl. 21(3), 1295\u20131303 (2021).","journal-title":"Am. J. Transpl."},{"issue":"1","key":"45750_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.NPR.0000722316.63824.f9","volume":"46","author":"R Clark","year":"2021","unstructured":"Clark, R., Waters, B. & Stanfill, A. G. Elevated liver function tests in COVID-19: Causes, clinical evidence, and potential treatments. Nurse Pract. 46(1), 21 (2021).","journal-title":"Nurse Pract."},{"key":"45750_CR49","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 323, 1239. https:\/\/doi.org\/10.1001\/jama.2020.2648 (2020).","journal-title":"JAMA"},{"key":"45750_CR50","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.4239\/wjd.v12.i7.1026","volume":"12","author":"R Viurcos-Sanabria","year":"2021","unstructured":"Viurcos-Sanabria, R. & Escobedo, G. Immunometabolic bases of type 2 diabetes in the severity of COVID-19, World. J. Diab. 12, 1026\u20131041. https:\/\/doi.org\/10.4239\/wjd.v12.i7.1026 (2021).","journal-title":"J. Diab."},{"key":"45750_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13098-020-00586-4","volume":"12","author":"B de Almeida-Pititto","year":"2020","unstructured":"de Almeida-Pititto, B. et al. Severity and mortality of COVID-19 in patients with diabetes, hypertension, and cardiovascular disease: A meta-analysis. Diabetol. Metab. Syndr. 12, 75. https:\/\/doi.org\/10.1186\/s13098-020-00586-4 (2020).","journal-title":"Diabetol. Metab. Syndr."},{"key":"45750_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2337\/dc21-1321","volume":"45","author":"J Ramon","year":"2021","unstructured":"Ramon, J. et al. Acute-to-chronic glycemic ratio as a predictor of COVID-19 severity and mortality. Diab. Care. 45, 255\u2013258. https:\/\/doi.org\/10.2337\/dc21-1321 (2021).","journal-title":"Diab. Care."},{"key":"45750_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","volume":"109","author":"B Li","year":"2020","unstructured":"Li, B. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 109, 531\u2013538. https:\/\/doi.org\/10.1007\/s00392-020-01626-9 (2020).","journal-title":"Clin. Res. Cardiol."},{"key":"45750_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4683","author":"G Onder","year":"2020","unstructured":"Onder, G., Rezza, G. & Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA https:\/\/doi.org\/10.1001\/jama.2020.4683 (2020).","journal-title":"JAMA"},{"key":"45750_CR55","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc20-2260","volume":"44","author":"JM Gregory","year":"2021","unstructured":"Gregory, J. M. et al. COVID-19 severity is tripled in the diabetes community: A prospective analysis of the pandemic\u2019s impact in type 1 and type 2 diabetes. Diab. Care. 44, 526\u2013532. https:\/\/doi.org\/10.2337\/dc20-2260 (2021).","journal-title":"Diab. Care."},{"key":"45750_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.dsx.2020.04.044","volume":"14","author":"A Kumar","year":"2020","unstructured":"Kumar, A. et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab. Syndr. 14, 535\u2013545. https:\/\/doi.org\/10.1016\/j.dsx.2020.04.044 (2020).","journal-title":"Diabetes Metab. Syndr."},{"key":"45750_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","volume":"17","author":"S Lim","year":"2021","unstructured":"Lim, S., Bae, J. H., Kwon, H.-S. & Nauck, M. A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 17, 11\u201330. https:\/\/doi.org\/10.1038\/s41574-020-00435-4 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"16","key":"45750_CR58","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/cid\/ciaa601","volume":"71","author":"R Fadel","year":"2020","unstructured":"Fadel, R. et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin. Infect. Dis. 71(16), 2114\u20132120 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"45750_CR59","doi-asserted-by":"publisher","first-page":"e01168","DOI":"10.1128\/AAC.01168-20","volume":"64","author":"A Fern\u00e1ndez-Cruz","year":"2020","unstructured":"Fern\u00e1ndez-Cruz, A. et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob. Agents Chemother. 64, e01168-e1220. https:\/\/doi.org\/10.1128\/AAC.01168-20 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"45750_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13054-020-02964-w","volume":"24","author":"X Lu","year":"2020","unstructured":"Lu, X., Chen, T., Wang, Y., Wang, J. & Yan, F. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit. Care. 24, 241. https:\/\/doi.org\/10.1186\/s13054-020-02964-w (2020).","journal-title":"Crit. Care."},{"key":"45750_CR61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/joim.13145","volume":"289","author":"F Sanz Herrero","year":"2021","unstructured":"Sanz Herrero, F. et al. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. J. Intern. Med. 289, 259\u2013263. https:\/\/doi.org\/10.1111\/joim.13145 (2021).","journal-title":"J. Intern. Med."},{"key":"45750_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-020-0158-2","volume":"5","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct. Target. Ther. 5, 57. https:\/\/doi.org\/10.1038\/s41392-020-0158-2 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"45750_CR63","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180, 934\u2013943. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994 (2020).","journal-title":"JAMA Intern. Med."},{"key":"45750_CR64","doi-asserted-by":"publisher","first-page":"e13319","DOI":"10.1111\/eci.13319","volume":"50","author":"DR Giacobbe","year":"2020","unstructured":"Giacobbe, D. R. et al. Bloodstream infections in critically ill patients with COVID-19. Eur. J. Clin. Invest. 50, e13319\u2013e13319. https:\/\/doi.org\/10.1111\/eci.13319 (2020).","journal-title":"Eur. J. Clin. Invest."},{"key":"45750_CR65","doi-asserted-by":"publisher","first-page":"e4208","DOI":"10.1093\/cid\/ciaa270","volume":"73","author":"P Mo","year":"2021","unstructured":"Mo, P. et al. Clinical characteristics of refractory coronavirus disease 2019 in Wuhan, China. Clin. Infect. Dis. 73, e4208\u2013e4213. https:\/\/doi.org\/10.1093\/cid\/ciaa270 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"45750_CR66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2020.06.091","volume":"98","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int. J. Infect. Dis. 98, 252\u2013260. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.091 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"45750_CR67","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/CM9.0000000000000774","volume":"133","author":"Y Ling","year":"2020","unstructured":"Ling, Y. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin. Med. J. Engl. 133, 1039\u20131043. https:\/\/doi.org\/10.1097\/CM9.0000000000000774 (2020).","journal-title":"Chin. Med. J. Engl."},{"key":"45750_CR68","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/cid\/ciaa351","volume":"71","author":"K Xu","year":"2020","unstructured":"Xu, K. et al. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 71, 799\u2013806. https:\/\/doi.org\/10.1093\/cid\/ciaa351 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"45750_CR69","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5694\/mja2.50577","volume":"212","author":"L Zha","year":"2020","unstructured":"Zha, L. et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust. 212, 416\u2013420. https:\/\/doi.org\/10.5694\/mja2.50577 (2020).","journal-title":"Med. J. Aust."},{"key":"45750_CR70","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijid.2020.03.047","volume":"94","author":"C Zheng","year":"2020","unstructured":"Zheng, C. et al. Risk-adapted treatment strategy for COVID-19 patients. Int. J. Infect. Dis. 94, 74\u201377. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.047 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"45750_CR71","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","volume":"27","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ. 27, 1451\u20131454. https:\/\/doi.org\/10.1038\/s41418-020-0530-3 (2020).","journal-title":"Cell Death Differ."},{"key":"45750_CR72","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/TP.0000000000003670","volume":"105","author":"YB Hadi","year":"2021","unstructured":"Hadi, Y. B., Naqvi, S. F. Z., Kupec, J. T., Sofka, S. & Sarwari, A. Outcomes of COVID-19 in solid organ transplant recipients: A propensity-matched analysis of a large research network. Transplantation 105, 1365\u20131371. https:\/\/doi.org\/10.1097\/TP.0000000000003670 (2021).","journal-title":"Transplantation"},{"key":"45750_CR73","doi-asserted-by":"publisher","first-page":"e13371","DOI":"10.1111\/tid.13371","volume":"22","author":"E Demir","year":"2020","unstructured":"Demir, E. et al. COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul. Transpl. Infect. Dis. 22, e13371\u2013e13371. https:\/\/doi.org\/10.1111\/tid.13371 (2020).","journal-title":"Transpl. Infect. Dis."},{"key":"45750_CR74","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/ajt.16351","volume":"21","author":"R Craig-Schapiro","year":"2021","unstructured":"Craig-Schapiro, R. et al. COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. Am. J. Transpl. 21, 1576\u20131585. https:\/\/doi.org\/10.1111\/ajt.16351 (2021).","journal-title":"Am. J. Transpl."},{"key":"45750_CR75","doi-asserted-by":"publisher","unstructured":"W.H.O.R.E.A. for C-19 T. (REACT) W. Group, J.A.C. Sterne, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: A Meta-analysis. JAMA 324, 1330\u20131341 (2020) DOI: https:\/\/doi.org\/10.1001\/jama.2020.17023.","DOI":"10.1001\/jama.2020.17023"},{"issue":"1177","key":"45750_CR76","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/cid\/ciaa1177","volume":"72","author":"CMP Jeronimo","year":"2021","unstructured":"Jeronimo, C. M. P. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized, double-blind, phase IIb, Placebo-controlled trial. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 72(1177), 373-e381. https:\/\/doi.org\/10.1093\/cid\/ciaa1177 (2021).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"45750_CR77","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.15537\/smj.2021.42.10.20210551","volume":"42","author":"NE Al-Otaibi","year":"2021","unstructured":"Al-Otaibi, N. E. A review of the evidence for and against the use of steroids in renal transplant patients with COVID-19. Saudi Med. J. 42, 1149\u20131152. https:\/\/doi.org\/10.15537\/smj.2021.42.10.20210551 (2021).","journal-title":"Saudi Med. J."},{"key":"45750_CR78","doi-asserted-by":"publisher","first-page":"6650469","DOI":"10.1155\/2021\/6650469","volume":"2021","author":"T Sahilu","year":"2021","unstructured":"Sahilu, T., Sheleme, T. & Melaku, T. Severity and mortality associated with steroid use among patients with COVID-19: A systematic review and meta-analysis. Interdiscip. Perspect. Infect. Dis. 2021, 6650469. https:\/\/doi.org\/10.1155\/2021\/6650469 (2021).","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"45750_CR79","doi-asserted-by":"publisher","first-page":"CD010406","DOI":"10.1002\/14651858.CD010406.pub3","volume":"2","author":"L Lansbury","year":"2019","unstructured":"Lansbury, L., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J. & Lim, W. S. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst. Rev. 2, CD010406\u2013CD010406. https:\/\/doi.org\/10.1002\/14651858.CD010406.pub3 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"45750_CR80","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s43088-021-00165-0","volume":"10","author":"VK Patel","year":"2021","unstructured":"Patel, V. K. et al. Corticosteroids for treatment of COVID-19: Effect, evidence, expectation and extent. Beni Suef Univ. J. Basic Appl. Sci. 10, 78. https:\/\/doi.org\/10.1186\/s43088-021-00165-0 (2021).","journal-title":"Beni Suef Univ. J. Basic Appl. Sci."},{"key":"45750_CR81","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/bjophthalmol-2020-316586","volume":"105","author":"ZX Thng","year":"2021","unstructured":"Thng, Z. X. et al. COVID-19 and immunosuppression: A review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. Br. J. Ophthalmol. 105, 306\u2013310. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316586 (2021).","journal-title":"Br. J. Ophthalmol."},{"key":"45750_CR82","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","volume":"92","author":"AH de Wilde","year":"2011","unstructured":"de Wilde, A. H. et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J. Gen. Virol. 92, 2542\u20132548. https:\/\/doi.org\/10.1099\/vir.0.034983-0 (2011).","journal-title":"J. Gen. Virol."},{"key":"45750_CR83","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12879-016-1492-4","volume":"16","author":"M Al Ghamdi","year":"2016","unstructured":"Al Ghamdi, M. et al. Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect. Dis. 16, 174. https:\/\/doi.org\/10.1186\/s12879-016-1492-4 (2016).","journal-title":"BMC Infect. Dis."},{"key":"45750_CR84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.antiviral.2016.07.019","volume":"133","author":"C Ma","year":"2016","unstructured":"Ma, C., Li, F., Musharrafieh, R. G. & Wang, J. Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance. Antivir. Res. 133, 62\u201372. https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.019 (2016).","journal-title":"Antivir. Res."},{"key":"45750_CR85","doi-asserted-by":"publisher","first-page":"104620","DOI":"10.1016\/j.antiviral.2019.104620","volume":"173","author":"Y Ma-Lauer","year":"2020","unstructured":"Ma-Lauer, Y. et al. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antivir. Res. 173, 104620. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104620 (2020).","journal-title":"Antivir. Res."},{"key":"45750_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.virusres.2012.02.002","volume":"165","author":"J Carbajo-Lozoya","year":"2012","unstructured":"Carbajo-Lozoya, J. et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 165, 112\u2013117. https:\/\/doi.org\/10.1016\/j.virusres.2012.02.002 (2012).","journal-title":"Virus Res."},{"key":"45750_CR87","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1111\/ajt.16250","volume":"20","author":"NN Poulsen","year":"2020","unstructured":"Poulsen, N. N., von Brunn, A., Hornum, M. & Blomberg Jensen, M. Cyclosporine and COVID-19: Risk or favorable?. Am. J. Transplant. 20, 2975\u20132982. https:\/\/doi.org\/10.1111\/ajt.16250 (2020).","journal-title":"Am. J. Transplant."},{"key":"45750_CR88","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2018.05.007","volume":"155","author":"HS Li","year":"2018","unstructured":"Li, H. S. et al. Effect of interferon alpha and cyclosporine treatment separately and in combination on middle east respiratory syndrome coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antivir. Res. 155, 89\u201396. https:\/\/doi.org\/10.1016\/j.antiviral.2018.05.007 (2018).","journal-title":"Antivir. Res."},{"key":"45750_CR89","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Respir. Med. 8, 420\u2013422. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X (2020).","journal-title":"Lancet. Respir. Med."},{"key":"45750_CR90","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.healun.2020.03.007","volume":"39","author":"S Aslam","year":"2020","unstructured":"Aslam, S. & Mehra, M. R. COVID-19: Yet another coronavirus challenge in transplantation. J. Heart Lung Transplant. 39, 408\u2013409. https:\/\/doi.org\/10.1016\/j.healun.2020.03.007 (2020).","journal-title":"J. Heart Lung Transplant."},{"key":"45750_CR91","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/tp.0b013e3182247b5f","volume":"92","author":"F Abadja","year":"2011","unstructured":"Abadja, F., Atemkeng, S., Alamartine, E., Berthoux, F. & Mariat, C. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation 92, 396\u2013403. https:\/\/doi.org\/10.1097\/tp.0b013e3182247b5f (2011).","journal-title":"Transplantation"},{"key":"45750_CR92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","volume":"184","author":"J Carbajo-Lozoya","year":"2014","unstructured":"Carbajo-Lozoya, J. et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. 184, 44\u201353. https:\/\/doi.org\/10.1016\/j.virusres.2014.02.010 (2014).","journal-title":"Virus Res."},{"key":"45750_CR93","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","volume":"115","author":"K-W Cheng","year":"2015","unstructured":"Cheng, K.-W. et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of middle east respiratory syndrome coronavirus. Antivir. Res. 115, 9\u201316. https:\/\/doi.org\/10.1016\/j.antiviral.2014.12.011 (2015).","journal-title":"Antivir. Res."},{"key":"45750_CR94","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","volume":"150","author":"M-H Lin","year":"2018","unstructured":"Lin, M.-H. et al. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antivir. Res. 150, 155\u2013163. https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.015 (2018).","journal-title":"Antivir. Res."}],"updated-by":[{"DOI":"10.1038\/s41598-023-48743-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45750-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45750-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45750-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:07:00Z","timestamp":1702987620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45750-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45750"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45750-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-023-48743-9","URL":"https:\/\/doi.org\/10.1038\/s41598-023-48743-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19002"}}